Literature DB >> 30893720

[Clinical features and short-term prognosis of Holmes' tremor].

Z Q Liu1, Z R Wan2, X T Jia1, X Z Yang3, X X Fang4, Z Y Zhang5.   

Abstract

Objective: To explore the clinical characteristics and short-term prognosis of Holmes' tremor (HT) patients.
Methods: The clinical and imaging data of HT patients in 5 teaching hospitals between January 2014 and January 2018 were retrospectively analyzed, and Fahn-Tolosa-Marin Tremor Rating Scale (TRS) was used to compare the clinical severity and short-term prognosis between the different subtypes.
Results: (1) The time from primary disease to tremor onset was 2 days to 20 months (median time 29 d) in 23 patients with HT enrolled, and the most common cause of HT was cerebrovascular disease (78.3%). (2) The most common involved locations were midbrain (65.2%), thalamus (47.8%) and cerebellum (30.4%). No significant difference in total TRS scores between the isolated lesion group (12 cases) and multiple lesions group (11 cases) (P=0.57), while the scores of the mesencephalic group (15 cases) was significantly higher than the non-mesencephalic group (8 cases) (P=0.00). (3) One case was treated with deep brain stimulation (DBS), while 22 cases were treated with medical therapy. Levodopa combined with clonazepam (7/12) and single levodopa (9/20) were partially effective. (4) At the 3-month follow-up after discharge, patients received DBS had good prognosis. Among the 22 patients treated with medicine, only 8 (36.4%) patients had good outcomes. The short-term prognosis was not significantly different between the isolated and multiple lesion groups (P=0.40), while it was worse in the mesencephalic group than the non-mesencephalic group (P=0.02).
Conclusion: The most common cause of HT is cerebrovascular disease, and primary lesions are midbrain, thalamus, and cerebellum. The pharmacologic agents are partially valid for disease control of HT and the short-term prognosis is poor, while the patients with mesencephalic involvement have more severe tremor and worse prognosis.

Entities:  

Keywords:  Cerebrovascular disease; Deep brain stimulation; Holmes′ tremor; Levodopa; Midbrain

Mesh:

Year:  2019        PMID: 30893720     DOI: 10.3760/cma.j.issn.0376-2491.2019.11.001

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  3 in total

Review 1.  Clinical Features, Neuroimaging, and Levodopa-Responsiveness in Holmes' Tremor: A Video-Based Case-Series with a Review of the Literature.

Authors:  Anumeha Mishra; Sanjay Pandey
Journal:  Mov Disord Clin Pract       Date:  2022-07-07

Review 2.  Holmes tremor: an updated review.

Authors:  Efstratios-Stylianos Pyrgelis; Eleni Agapiou; Efthalia Angelopoulou
Journal:  Neurol Sci       Date:  2022-08-25       Impact factor: 3.830

3.  Study on the pathogenesis of Holmes tremor by multimodal 3D medical imaging: case reports of three patients.

Authors:  Min Shi; Anrong Wang; Yu Fang; Jun Guo; Zhaoying Li; Suoguo Jin; Huan Zhao
Journal:  BMC Neurol       Date:  2021-12-06       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.